With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Most patients with chronic myeloid leukemia have deep and durable responses when
treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs). Imatinib (the first approved TKI) …

Vascular endothelial growth factors (VEGFs) bind to membrane receptors on a wide variety
of cells to regulate diverse biological responses. The VEGF-A family member promotes …

Ponatinib is a tyrosine kinase inhibitor (TKI) directed against BCR-ABL1 which is
successfully used in patients with BCR-ABL1 T315I+ chronic myeloid leukemia (CML) …

The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high
rates of acute ischemic events. The pathophysiology responsible for these events is …

Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I
mutation. In different trials this drug showed inhibitory activity against native BCR-ABL1 …

Abstract Aims Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic
myelogenous leukaemia (CML). However, cardiotoxicity of these agents remains a serious …